A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: Relationship with leukocytopenia and neutropenia

International Journal of Hematology

Volumn 74, Issue 3, 2001, Pages 297-302

  Fukushima, Toshihiro ^a,b   Yamashita, Taro ^b   Goto, Nobuyuki ^b   Ueda, Takanori ^b,c   Okabe, Ken Ichi ^c,d   Kuraishi, Yasunobu ^c,e   Ohno, Ryuzo ^c,f,g   Urabe, Akio ^c,h   Ogawa, Makoto ^c,g  

^a National Kanazawa Hospital   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c Idarubicin Study Group   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h Kanto Teishin Hospital   (Japan)

Author keywords

Idarubicin; Idarubicinol; Malignant lymphoma; Pharmacokinetics

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DRUG DERIVATIVE; IDARUBICIN; IDARUBICINOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HALF LIFE TIME; HUMAN; IATROGENIC DISEASE; JAPAN; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOMA; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL;

AGED; ANTIBIOTICS, ANTHRACYCLINE; AREA UNDER CURVE; BIOTRANSFORMATION; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMAN; IDARUBICIN; JAPAN; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOMA; MALE; MIDDLE AGE; NEUTROPENIA;

EID: 0035488468     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982064     Document Type: Article

References (28)

1. Arcamone F, Bernardi L, Giardino P, et al. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7, 9-diepidaunorubicin, and their β anomers. Cancer Treat Rep. 1976;60:829-834.
2. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666-1674.
3. Vogler WR, Velez-Garcia E, Weiner RS. et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992;10:1103-1111.
4. Wiernik PH, Banks PLC, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313-319.
5. Bassan R, Di Bona E, Lerede T, et al. Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. Leuk Lymph. 1996;22: 295-301.
6. Giona F, Testi AM, Annino L, et al.Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Br J Haematol. 1994;86:55-61.
7. Case DC Jr, Gerber MC, Gams RA, et al. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. Cancer Res. 1992;52:3871-3874.
8. Dufour P, Mors R, Berthaud P, et al. Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma. Leuk Lymph. 1996;22:329-334.
9. Ballester OF, Moscinski LC, Fields KK, et al. Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. Br J Haematol. 1997;96:746-748.
10. Barnadas A, Mendiola C, Casado A, et al. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study. Eur J Cancer. 1997;33:312-315.
11. Loveless H, Arena E, Felsted RL, Bachur NR. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res. 1978;38:593-598.
12. Speth PAJ, Minderman H, Haanen C. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol. 1989;16(suppl 2):2-9.
13. Ueda T, Fukushima T. Recent developments with novel anthracyclines for the treatment of haematological malignancies. Exp Opin Invest Drugs. 1996;5:1639-1646.
14. Schott B, Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem Pharmacol. 1989;38:4069-4074.
15. Fukushima T, Kawai Y, Urasaki Y, Yoshida A, Ueda T, Nakamura T. Influence of idarubicinol on the antileukemic effect of idarubicin. Leuk Res. 1994;18:943-947.
16. Fukushima T, Yamashita T, Yoshio N, et al. Effect of PSC833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells. Leuk Res. 1999;23:37-42.
17. Fukushima T, Inoue H, Takemura H, et al. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin. Leuk Res. 1998;22:625-629.
18. Minderman H, Linssen P, van der Lely N, et al.Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia. 1994;8:382-387.
19. Urabe A, Ohno R, Kuraishi Y, Masaoka T, Ohashi Y, Ogawa M. Clinical effect of idarubicin on malignant lymphoma. Jpn J Cancer Chemother [in Japanese]. 1999;26:1275-1282.
20. Moro E, Bellotti V, Jannuzzo MG, Stegnjaich S, Valzelli G. High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydroderivative. J Chromatogr. 1983;247:281-287.
21. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokin Biopharm. 1978;6:547-558.
22. Riggs CE Jr. Clinical pharmacology of daunorubicin in patients with acute leukemia. Semin Oncol. 1984;11(suppl 3):2-11.
23. Broggini M, Italia C, Colombo T, Marmonti L, Donelli MG. Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep. 1984;68:739-747.
24. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993;24:275-288.
25. Pannuti F, Camaggi CM, Strocchi E, Comparsi R, Angelelli B, Pacciarini MA. Low dose oral administration of 4-demethoxy-daunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. Cancer Chemother Pharmac. 1986;16:295-299.
26. Stewart DJ, Grewaal D, Green RM, et al. Bioavailability and pharmacology of oral idarubicin. Cancer Chemother Pharmac. 1991;27:308-314.
27. Ueda T, Nakamura T, Kagawa D, et. al. Intracellular distribution of N4-behenoyl-l-β-D-arabinofuranosylcytosine in blood cells. Gann. 1983;74:445-451.
28. Elbaek K, Ebbehoj E, Jakobsen A, et al. Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects, Clin Pharmacol Ther. 1989;45:627-634.